insulin detemir vs Insulin Efsitora Alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin detemir · Levemir

Rights held by Novo Nordisk; US product discontinued

Approved in Type 2 Diabetespeptide
Partial signal

NCT00283751 · Phase 3 · completed

The study randomized 583 participants to insulin detemir or insulin glargine, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07) (met)

Result source: NCT00856986

Insulin Efsitora Alfa · Onswik

Marketed by Eli Lilly

Approved in Type 2 Diabetesprotein (Fc-fusion)
Partial signal

NCT05275400 · Phase 3 · completed

The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)

Result source: NCT05662332

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin detemirInsulin Efsitora Alfa
HbA1c, change-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
Body weight, change (kg)-0.1 vs -1.0vs Lira 1.8wk 52 · n 162NCT00856986
8 other results
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • 3.6 vs 6.4 wk 156 · n 234 · Phase 3 · secondary NCT00184600
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
HbA1c below 7%—Not posted · NCT00604396—Not reported
Fasting plasma glucose, change-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
—Not reported
3-point MACE (% with event)—Not posted · NCT00604396—Not reported

HbA1c, change

insulin detemir
-0.5% vs 0.0%vs Lira 1.8wk 26 · n 160NCT00856986
6 other results
  • -0.5% vs -0.1% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -0.5% vs 0.0% wk 52 · n 160 · Phase 3 · secondary NCT00856986
  • -1.0% vs -1.1% wk 32 · n 195 · Phase 4 · primary NCT01165684
  • -0.5% vs -0.7% wk 26 · n 209 · Phase 4 · primary NCT00909480
  • -0.8% vs -1.1% wk 21 · n 195 · Phase 4 · secondary NCT01165684
  • -0.5% vs -1% wk 10 · n 193 · Phase 4 · secondary NCT01165684
Insulin Efsitora Alfa
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394

Body weight, change (kg)

insulin detemir
-0.1 vs -1.0vs Lira 1.8wk 52 · n 162NCT00856986
8 other results
  • 1.9 vs 5.7 wk 52 · n 234 · Phase 3 · secondary NCT00184600
  • -0.2 vs -0.9 wk 26 · n 162 · Phase 3 · secondary NCT00856986
  • -0.8 vs -1.7 wk 26 · n 103 · Phase 3 · secondary NCT00789191
  • 3.6 vs 6.4 wk 156 · n 234 · Phase 3 · secondary NCT00184600
  • -0.5 vs 1 wk 26 · n 196 · Phase 4 · secondary NCT00909480
  • 0.3 vs 0.8 wk 26 · n 22 · Phase 4 · secondary NCT00998335
  • 13 vs 12.6 n 45 · Phase na · secondary NCT01837680
  • 1.2 vs 2.8 Phase 3 · primary NCT00604396
Insulin Efsitora Alfa
3.6 vs 3.5vs Insulin Degludecwk 52 · n 465NCT05362058
6 other results
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 2.3 vs 2.2 500 U/mL · wk 78 · n 654 · Phase 3 · secondary NCT05275400
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785

HbA1c below 7%

insulin detemir
—Not posted · NCT00604396
Insulin Efsitora Alfa
—Not reported

Fasting plasma glucose, change

insulin detemir
-1.9 vs -0.1vs Lira 1.8wk 52 · n 160NCT00856986
2 other results
  • -2.1 vs -0.4 wk 26 · n 160 · Phase 3 · secondary NCT00856986
  • 6.4 vs 4.9 wk 26 · n 22 · Phase 4 · secondary NCT00998335
Insulin Efsitora Alfa
—Not reported

3-point MACE (% with event)

insulin detemir
—Not posted · NCT00604396
Insulin Efsitora Alfa
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin detemir: 4 of 4 rows · Insulin Efsitora Alfa: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin detemir
Rows use multiple source trials
Insulin Efsitora Alfa
Dropout rate
0%a
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
8.7%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
13.9%
NCT01165684 · Phase 4 · registry result, not featured evidence
16.7%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
6.9%
NCT00455858 · Phase 4 · registry result, not featured evidence
12.3%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
14.8%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
19.2%
NCT00184600 · Phase 3 · registry result, not featured evidence
12.6%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
18.2%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
15.1%
NCT01837680 · Phase na · registry result, not featured evidence
9.5%500 U/mLb
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
5.4%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
8.8%Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
12.6%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
12.9%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0%a
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
—Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
—Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
0.5%
NCT01165684 · Phase 4 · registry result, not featured evidence
2.2%
NCT00909480 · Phase 4 · registry result, not featured evidence
—
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
—
NCT00591227 · Phase 4 · registry result, not featured evidence
—
NCT00455858 · Phase 4 · registry result, not featured evidence
1.6%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
2.5%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
3.8%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.8%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
—Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
—Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
—
NCT01837680 · Phase na · registry result, not featured evidence
1.1%500 U/mLb
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
0.6%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
0.7%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
0.8%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Serious AEs
10.4%a
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 16 more results
4.3%Insulin Detemir (2-4-6-8 Algorithm
NCT01868542 · Phase 4 · registry result, not featured evidence
0%Insulin Detemir (3-0-3 Algorithm )
NCT01868542 · Phase 4 · registry result, not featured evidence
9.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
3.1%
NCT00909480 · Phase 4 · registry result, not featured evidence
0%
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00591227 · Phase 4 · registry result, not featured evidence
5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
4.1%FPG 70-90 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
3.3%FPG 80-110 mg/dL
NCT00634842 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
22.4%
NCT00590226 · Phase 4 · registry result, not featured evidence · combination
33.3%
NCT00184600 · Phase 3 · registry result, not featured evidence
1.9%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
0%Iiraglutide
NCT01232946 · Phase na · registry result, not featured evidence
0%Liraglutide Plus Insulin Detemir
NCT01232946 · Phase na · registry result, not featured evidence · combination
0%
NCT01837680 · Phase na · registry result, not featured evidence
15.7%500 U/mLb
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
8.8%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.7%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
7.1%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
5.2%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
6.1%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 20.2%
nausea 18.4%
diarrhoea 17.8%
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 13 more results
nasopharyngitis 13%
headache 8.7%
upper respiratory tract infection 4.3%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 13%
rash 8.7%
upper respiratory tract infection 8.7%
NCT01868542 · Phase 4 · registry result, not featured evidence
nasopharyngitis 8.1%
headache 5.1%
influenza 5.1%
NCT01165684 · Phase 4 · registry result, not featured evidence
nasopharyngitis 10.6%
upper respiratory tract infection 8%
headache 7.5%
NCT00909480 · Phase 4 · registry result, not featured evidence
nasopharyngitis 11.5%
upper respiratory tract infection 5.7%
NCT00455858 · Phase 4 · registry result, not featured evidence
back pain 5.8%
headache 5%
upper respiratory tract infection 5%
NCT00634842 · Phase 4 · registry result, not featured evidence
pain in extremity 3.3%
urinary tract infection 3.3%
anxiety 2.5%
NCT00634842 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 46.2%
diarrhoea 25.6%
infection 21.4%
NCT00184600 · Phase 3 · registry result, not featured evidence
headache 14.5%
nasopharyngitis 13.2%
back pain 10.5%
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
gastrointestinal intolerance 0%
NCT01232946 · Phase na · registry result, not featured evidence
gastrointestinal intolerance 18.2%
NCT01232946 · Phase na · registry result, not featured evidence · combination
biochemical event of hypoglycemia 50.9%
symptomatic hypoglycemia 30.2%
symptomatic nocturnal event 15.1%
NCT01837680 · Phase na · registry result, not featured evidence
500 U/mLb
covid-19 10.7%
nasopharyngitis 9.2%
dose calculation error 6.4%
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 7 more results
nasopharyngitis 9.2%
covid-19 7.9%
upper respiratory tract infection 7.9%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
anaemia 4.7%
arthralgia 2.3%
diarrhoea 2.3%
NCT04450394 · Phase 2 · registry result, not featured evidence
abdominal discomfort 7.1%
anaemia 7.1%
chest pain 7.1%
NCT04450394 · Phase 2 · registry result, not featured evidence
diarrhoea 6.7%
upper respiratory tract infection 5.9%
cough 0.7%
NCT03736785 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 10.6%
diarrhoea 6.1%
dizziness 5.3%
NCT03736785 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 16 of these studies.
  2. bPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin detemir

Fasting Plasma Glucose -2.12 vs -0.39 Lira 1.8 mmol/L @ 26wk
absolute change · mmol/L
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
-1.91 vs -0.14 Lira 1.8 mmol/L @ 52wk
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
NA vs 5.83 Insulin Detemir mmol/L @ 13wk
NCT00998335 · Phase 4 · registry result, not featured evidence · combination
6.44 vs 4.94 Insulin Detemir mmol/L @ 26wk*
NCT00998335 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from 116 mg/dL as posted
Waist Circumference Change -0.78 vs -0.66 Lira 1.8 cm @ 26wk
absolute change · cm
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
Waist Circumference Change -0.83% (n=160) vs -0.83% (n=148) Lira 1.8 @ 52wk
absolute change · percentage points
NCT00856986 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c -0.9% (n=23) @ 20wk
absolute change · percentage points
No placebo or comparator arm
NCT01868542 · Phase 4 · registry result, not featured evidence
show 5 more results
-1% (n=21) @ 20wk
NCT01868542 · Phase 4 · registry result, not featured evidence
-0.8% (n=23) @ 12wk
NCT01868542 · Phase 4 · registry result, not featured evidence
-0.9% (n=21) @ 12wk
NCT01868542 · Phase 4 · registry result, not featured evidence
-1.229% (n=111) @ 20wk
NCT00634842 · Phase 4 · registry result, not featured evidence
-0.958% (n=112) @ 20wk
NCT00634842 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -4.12 mmol/L @ 12wk
absolute change · mmol/L
No placebo or comparator arm
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -74.3 mg/dL as posted
show 3 more results
-2.48 mmol/L @ 12wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -44.6 mg/dL as posted
-3.35 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -60.4 mg/dL as posted
-3.89 mmol/L @ 20wk*
NCT01868542 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -70 mg/dL as posted
HbA1c Less Than 7 19.2% (n=193) vs 56.3% (n=183) insulin aspart @ 10wk
absolute value · percentage points
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
45.1% (n=195) vs 65.4% (n=188) insulin aspart @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
55.9% (n=195) vs 63.3% (n=188) insulin aspart @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose 7.1 vs 6.7 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 5 more results
7.1 vs 7 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
7.12 vs 7.01 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
6.22 vs 6.09 IGlar mmol/L @ 26wk
NCT00909480 · Phase 4 · registry result, not featured evidence
6.08 vs 8.52 Sitagliptin mmol/L @ 26wk
NCT00789191 · Phase 3 · registry result, not featured evidence · combination
5.4 vs 5.59 Insulin NPH mmol/L*
NCT01837680 · Phase na · registry result, not featured evidence · converted to mmol/L from 97.3 mg/dL as posted
Postprandial Glucose Increment 2.3 vs 1.4 insulin aspart mmol/L @ 10wk
absolute value · mmol/L
NCT01165684 · Phase 4 · registry result, not featured evidence
show 2 more results
1.9 vs 1.5 insulin aspart mmol/L @ 21wk
NCT01165684 · Phase 4 · registry result, not featured evidence
1.64 vs 1.28 insulin aspart mmol/L @ 32wk
NCT01165684 · Phase 4 · registry result, not featured evidence
Body Weight 89.32 vs 89.8 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
BMI 31.86 vs 32.03 insulin aspart kg @ 32wk
absolute value · kg
NCT01165684 · Phase 4 · registry result, not featured evidence
HbA1c 7 0 or Less 38% (n=209) vs 53% (n=204) IGlar @ 26wk
responder rate · % of participants
All
NCT00909480 · Phase 4 · registry result, not featured evidence
HbA1c Less Than 7 Without Hypoglycemia 32% (n=209) vs 38% (n=204) IGlar @ 26wk
absolute value · percentage points
All
NCT00909480 · Phase 4 · registry result, not featured evidence

+ 34 further endpoints in the CSV export.

Insulin Efsitora Alfa

Time in Range 61.37% (n=641) vs 60.95% (n=325) Insulin Degludec @ 26wk500 U/mL
absolute value · percentage points
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
66.12% (n=385) vs 65.85% (n=382) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
58.39% (n=359) vs 57.05% (n=360) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Fasting Glucose Change mg/dL -30.97 vs -30.13 Insulin Degludec mg @ 26wk500 U/mL
absolute change · mg
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
-46.76 vs -50.92 Glargine mg @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-30.87 vs -26.58 Insulin Glargine mg @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.1 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
-18.6 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
Time Below Range 0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mL
absolute value · % of time
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
6.84 vs 5.25 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above Range 37.25 vs 38.24 Insulin Degludec % of time @ 26wk500 U/mL
absolute value · % of time
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
31.99 vs 32.4 Insulin Degludec % of time @ 12wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.93 vs 29.87 Insulin Degludec % of time @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
29.66 vs 33.05 Insulin Degludec % of time @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
40.1 vs 41.6 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
TRIM-D 10.03 vs 6.88 Insulin Degludec score @ 26wk500 U/mL
absolute change · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
10.09 vs 6.53 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.33 vs 6.98 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 13.87 Glargine score @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 14.9 vs 12.3 Insulin Degludec score @ 26wk500 U/mL
absolute value · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
15.1 vs 12.3 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 11.7 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
FBG Change mg/dL -57.86 vs -63.04 Insulin Degludec mg @ 26wk
absolute change · mg
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-59.77 vs -59.97 Insulin Degludec mg @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Glucose Variability CV 26.31% (n=368) vs 26.67% (n=360) Insulin Degludec @ 26wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
26.29% (n=368) vs 26.81% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 70 mg/dL 1.06% (n=368) vs 0.93% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
1.55% (n=368) vs 1.25% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.49% (n=368) vs 1.19% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 54 mg/dL 0.24% (n=368) vs 0.27% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
0.33% (n=368) vs 0.28% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.32% (n=368) vs 0.3% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Hypoglycemia Event Incidence 25.94% (n=397) vs 29.9% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Nocturnal Hypoglycemia Incidence 3.53% (n=397) vs 5.03% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

+ 5 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin detemir's landscape · Insulin Efsitora Alfa's landscape